Talk Around Town: SpaceX CRS-35 May Have Just Hauled the Last Solar Arrays the ISS Will Ever Need

What Folks Are Saying: The Big Picture Chatter

Well, butter my biscuit and call it Tuesday—because that's exactly when a Falcon 9 rocket hauled itself off the launchpad at Cape Canaveral Space Force Station's SLC-40 at 6:33 a.m. EDT on October 13, 2026. NASA confirmed the liftoff on its station blog, and Spaceflight Now's live coverage independently corroborated every digit of that timestamp. The talk around town is that this particular Dragon—hull number C211—is carrying what NASA describes as a historic last load for the International Space Station.

The chatter centers on two big threads: first, that NASA says CRS-35 is hauling the final pair of Roll-Out Solar Arrays the ISS will ever need, closing out a power-upgrade saga that stretches back to 2021; and second, that tucked inside that same Dragon is what multiple outlets are calling a genuinely wild biotech science haul—artificial retinas, brain organoids, and 3D-printed heart tissue, all headed for Expedition 75. Now, Dragon was still en route when we typed this up, so hold your horses before you declare anything a done deal.

What Is Actually Known and Confirmed

NASA's own station blog and Spaceflight Now both confirm the launch facts without ambiguity: Cargo Dragon C211 is aloft, carrying what NASA reports as more than 6,300 pounds of science, supplies, and solar hardware. Arrival at the station was expected around 11 a.m. Thursday, October 15, according to NASA, with astronauts Anil Menon and Joshua Kutryk designated by Spaceflight Now to monitor Dragon's automated approach and docking.

Wikipedia's dedicated Roll Out Solar Array article and the CRS-35 mission page, cross-checked against NASA's prelaunch overview, confirm the iROSA completion narrative. According to those sources, the power-upgrade campaign kicked off with CRS-22 in 2021. NASA announced in May 2026 that a fall launch was the target, a date later shifted to August and then to October 2026 after a Baikonur launchpad fire in late 2025 reshuffled the schedule, per Wikipedia's CRS-35 article. The October 13 launch date is confirmed across multiple independent outlets.

On the crew side, NASA's blog confirms that Expedition 75 includes NASA astronauts Anil Menon, Jessica Watkins, and Luke Delaney, CSA astronaut Joshua Kutryk, and three Roscosmos cosmonauts. NASA reports that on launch day the crew was actively conducting biomedical research: eye imaging, Bio-Monitor wearable health tracking, 3D cell printing, and tele-operated ultrasound. Menon, Watkins, and Delaney used a medical imaging device for eye checks, according to NASA, helping doctors understand how microgravity affects retinal and corneal tissue.

The Science Manifest: What NASA and Specialists Are Claiming

According to NASA's blog and corroborated by Spaceflight Now, some of the new science aboard will explore creating artificial retinas and growing heart tissues in the weightless environment. Specialist outlet Tech Insider, relying on NASA's manifest announcement, reports that LambdaVision's hardware is flying for what the company describes as its ninth ISS mission. The experiment, per Tech Insider, tests whether microgravity's lack of sedimentation and convection currents produces more uniform protein-based retinal films than ground manufacturing can manage—the retina design being a roughly 200-layer thin-film implant intended to replace damaged photoreceptor cells, according to Tech Insider's analysis of the NASA manifest.

Two brain-organoid investigations—AVATAR-Org1 and MINDS—are included in the manifest, according to Tech Insider and Tesla North, both citing NASA's prelaunch materials. These studies, per those specialist sources, are aimed at neurodegenerative diseases including Alzheimer's, Parkinson's, and multiple sclerosis. Organoids have become a central neuroscience research tool over the past decade, and the microgravity environment is claimed by researchers, per Tech Insider, to offer unique growth conditions unavailable on the ground. None of the experimental outcomes will be known for weeks or months.

What Remains Unverified and Still Up in the Air

Lord have mercy, there's a whole pasture of unknowns here, and we'd be dumber than a bag of wet hammers to paper over them. Dragon had not yet docked at time of publishing, so the cargo transfer, the iROSA offloading, and every single experimental result are all downstream events that haven't happened yet. The spacewalks needed to actually install those final solar arrays have not been scheduled, according to the uncertainty note attached to this mission. So the 'completion' of the power-upgrade campaign is more of a 'completion of delivery'—the finish line is still a few EVAs away.

There's also a minor cargo-weight discrepancy worth flagging: a space calendar site listed Dragon's haul at 7,200 pounds, while NASA and most reporting outlets cite more than 6,300 pounds. The gap likely reflects different accounting methods—pressurized cargo only versus total mass including the unpressurized iROSA trunk payload—but it hasn't been formally reconciled in any source we reviewed. Tech Insider's specific experimental claims about LambdaVision and the organoid studies are drawn from NASA's manifest announcement and treated here as secondary interpretive reporting, not independently validated science.

Analysis: Why This Moment Feels Like a Turning Point

This is analysis, not settled reporting, so salt it accordingly. If the iROSA delivery and eventual installation go as planned, the ISS will have wrapped a five-year power-upgrade arc that began when the station's original solar wings started showing their age like an old tractor left out in three Alabama summers. Completing that arc while simultaneously flying protein retinas, brain organoids, and printed heart tissue suggests the station isn't winding down so much as pivoting—less construction site, more orbital laboratory, at least for whatever years remain in its operational life.

The biotech payload mix is striking in a way that feels deliberate rather than coincidental. LambdaVision's ninth mission points to a maturing research relationship between the ISS and private biotech, not a one-off experiment. Brain organoid studies targeting multiple neurodegenerative diseases in a single mission suggests researchers are treating microgravity as a genuine platform advantage, not just a novelty. Whether that advantage proves out in the actual data is, of course, a question that won't be answered until long after Dragon is back home. For now, the rocket flew, the cargo is en route, and the rest is one big beautiful question mark floating about 250 miles above our heads.